SAN FRANCISCO, CA--(Marketwired - April 17, 2014) - Medivation, Inc. (NASDAQ: MDVN) today announced that Patrick Machado has been appointed to the Company's board of directors. Mr. Machado recently retired from his role as chief financial and business officer, and will formally retire from Medivation on April 18, 2014.
"For the past nine years of having the honor of serving on the board of directors of Medivation, including seven as chairman, I've had the opportunity to observe the keen insight and vision that Pat Machado has brought to Medivation," said Kim D. Blickenstaff, chairman of Medivation, Inc. "I look forward to working with Pat in his new role, as he continues to help guide Medivation's efforts to develop novel therapies for serious diseases."
Mr. Machado previously served as Medivation's chief business officer since December 2009 and its chief financial officer since December 2004. From 1998 until 2001, Mr. Machado was employed by ProDuct Health, Inc., a privately held medical device company, as vice president, chief financial officer and general counsel (1998-2000) and as senior vice president and chief financial officer (2000-2001). From 2001 until 2002, Mr. Machado served as a consultant to Cytyc Corporation to assist with transitional matters related to Cytyc Corporation's acquisition of ProDuct Health, Inc. Mr. Machado received a J.D. from Harvard Law School and a B.A. and B.S. in German and Economics, respectively, from Santa Clara University.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at www.medivation.com.